Acrivon Therapeutics (NASDAQ:ACRV) Posts Earnings Results, Beats Estimates By $0.02 EPS

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02, FiscalAI reports.

Acrivon Therapeutics Trading Up 0.7%

NASDAQ:ACRV traded up $0.01 during mid-day trading on Monday, hitting $1.46. The stock had a trading volume of 340,611 shares, compared to its average volume of 791,627. The stock has a 50-day simple moving average of $1.83 and a two-hundred day simple moving average of $1.75. The company has a market capitalization of $62.57 million, a PE ratio of -0.78 and a beta of 1.96. Acrivon Therapeutics has a twelve month low of $1.27 and a twelve month high of $3.56.

Insider Transactions at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen sold 14,036 shares of Acrivon Therapeutics stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total value of $31,019.56. Following the completion of the transaction, the chief executive officer owned 2,230,052 shares in the company, valued at $4,928,414.92. The trade was a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,345 shares of company stock valued at $37,578 in the last ninety days. 10.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ACRV has been the topic of several research reports. Jefferies Financial Group reissued a “buy” rating on shares of Acrivon Therapeutics in a research note on Wednesday, November 11th. Weiss Ratings upgraded Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Finally, Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.50.

Read Our Latest Analysis on ACRV

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

Read More

Earnings History for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.